Search results
Results from the WOW.Com Content Network
The Institute was founded in 1989 to provide a rich, collaborative environment for scientists working in diverse but complementary specialities in the fields of developmental biology and cancer biology. It receives its primary funding from the Wellcome Trust and Cancer Research UK. [6]
The Edinburgh Cancer Research Centre was established in The University of Edinburgh (UoE) in close partnership with Cancer Research UK and the NHS Lothian, and has strong links to other Institutes and Colleges conducting cancer research in Edinburgh, in particular the Institute of Genetics & Molecular Medicine. The ECRC follows a partnership ...
The Cancer Genome Project is part of the cancer, aging, and somatic mutation research based at the Wellcome Trust Sanger Institute in the United Kingdom. It aims to identify sequence variants / mutations critical in the development of human cancers .
The paper outlines a 10-point plan to improve cancer care, and calls for the creation of a UK-wide national cancer control plan, along with a prevention programme for smoking, obesity and alcohol ...
Scientific research at the Sanger Institute is organised into five Scientific Programmes, each defining a major area of research with a particular biological, disease or analytic focus. The current Programmes at the Sanger Institute are Cancer, Ageing and Somatic Mutation, Cellular Genetics, Human Genetics, Parasites and Microbes and Tree of Life.
In follow-up research at the ICR in 1964, Professors Peter Brookes and Philip Lawley proved that chemical carcinogens act by damaging DNA, leading to mutations and the formation of tumours, proving that cancer is a genetic disease based on mutational events. [7] In 1954 the institute was officially renamed The Institute of Cancer Research (ICR).
In 2007 the Human Genetics Unit formed a partnership with two neighbouring research centres on the Western General Hospital campus, the Centre for Genomic and Experimental Medicine (University of Edinburgh) and the Edinburgh Cancer Research Centre (Cancer Research UK), to create the Institute of Genetics and Molecular Medicine.
Carroll's research uses molecular, genomic and proteomic approaches to understand how the Estrogen Receptor causes gene transcription and how this contributes to breast cancer progression. [5] In 2008, Carroll discovered the molecular mechanism of tamoxifen in breast cancer, demonstrating that tamoxifen switched off the breast cancer gene ErbB2 ...